The Problem
A major barrier to early treatment is the blood-brain barrier (BBB). While it protects the brain from harmful substances, it also blocks most therapies from reaching neural tissue effectively. In fact, less than 2% of small molecules and almost no biologics cross the BBB at therapeutically relevant levels, making early neuroprotection extremely difficult.
As recent outbreaks have shown, neurological symptoms may appear only after viral entry has already begun. This means current medicine is often too reactive, too general, or too late to address neuroinvasion at the point where it matters most, increasing the risk of long-term neurological damage and reduced patient outcomes.
Many antiviral treatments are designed to reduce infection after it has already spread, but they do not specifically prevent viruses from reaching the brain during the earliest stages of disease. This is a major challenge because some viral infections have been associated with neurological complications such as inflammation, cognitive impairment, and long-term neuronal damage.